Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.
This study has been withdrawn prior to enrollment.
Information provided by:
First received: September 9, 2005
Last updated: March 19, 2012
Last verified: March 2012
This is a safety and efficacy study of add on therapy with seletracetam in patients experiencing refractory epilepsy.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Open Label, Multicenter Study of the Safety and Efficacy of Oral Treatment With Immediate Release Seletracetam (Ucb 44212) at Individualized Doses up to a Maximum of 160mg/Day in Refractory Epileptic Patients.|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by UCB, Inc.:
Contacts and Locations